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Psychometric Properties of the Persian-Version of Myocardial Infarction Dimensional 
Assessment Scale  
 
Abstract 
Assessment of quality of life is an important measure of the impact of the disease, and 
effectiveness of treatment. The myocardial infarction dimensional assessment scale is a disease-
specific questionnaire developed for the evaluation of health-related quality of life in patients 
following myocardial infarction. The purpose of this study was to determine the psychometric 
properties, the Persian version of myocardial infarction dimensional assessment scale. The 
translated version of scale was checked for validity and reliability with 350 patients who had 
suffered a myocardial infarction within the last 90 days. Participants were recruited from five 
inpatient wards and two outpatient departments at four university hospitals in Tehran between 
June 2013 and March 2014. Exploratory factor analysis indicated a six-factor solution for the 
questionnaire: ‘physical activity’, ‘insecurity’, ‘emotional reaction’, ‘dependency’, ‘diet’, and 
‘concerns over medication and side effects’. Together, these accounted for 81.63% of variance 
observed. Cronbach’s alpha of the subscales ranged from 0.88 to 0.98 and test-retest reliability 
intraclass correlation coefficients ranged from 0.81 to 0.97 indicating that the instrument was 
reliable. This study gave evidence of reliability and validity of the Persian Version of Myocardial 
Infarction Dimensional Assessment Scale. The MIDAS scale-Persian version is demonstrated to 
have an acceptable reliability and validity in Iranian patients with Myocardial Infarction. This 
scale can be used to measure health outcomes in different clinical settings and research centres; 
Moreover, it can be used by nurses over the world for both measuring health-related quality of 
life and determine the effects of different medical and nursing interventions on patients’ quality 
of life. 
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Introduction 
Cardiovascular disease (CVD) is the leading cause of death and disability in both developing and 
developed countries. It accounted for less than 10% of global mortality at the beginning of the 
twentieth century, and over 30% of all deaths a hundred years later, Over 80% of CVD deaths 
take place in low- and middle-income countries (Hatmi et al. 2007; Lloyd-Jones et al. 2010; 
WHO, 2014) and it is one of the most common causes of hospitalisation in industrial countries 
(Badir and Sepit, 2007). By 2030, nearly 23.3 million deaths each year will be due to 
cardiovascular diseases (WHO, 2014). In the UK, it has been predicted that the number of cases 
of CVD will rise by 44% and its related hospital admissions will increase by 32% (Quinn, 2009). 
The ongoing investigations illustrate that in the Eastern Mediterranean and Middle Eastern 
countries, CVD is growing in prevalence with a high number of remaining disabilities (Ham and 
Kim 2010, Lamotte et al., 2010). CVD has become an important cause of mortality in Eastern 
Mediterranean countries, the Middle East and Iran, where it is termed the epidemic of the 
twentieth century (Fakhrzadeh et al. 2000). In Iran, 35% of deaths are due to CVD, and CVD is 
the leading cause of death in adults aged 35 years and older (AghaYousef et al. 2013).  CVD as a 
clinical syndrome affects many aspects of patients’ life (Demir and Unsar, 2011). One of the 
most challenging healthcare issues is to provide quality care for patients with CVD (Spertus et al. 
2003). Therefore, it is equally important that nurses be adequately prepared to assess such 
patients (Paavilainen et al. 2006). Those patients who survive a CVD event may live for an 
extended period of time, but often may be disabled. This highlights the need to attend to Health-
related quality of life (HRQL) in the studies regarding CVD (Dougher et al. 2000; Hofer, 2004). 
According to Iqbal et al. (2010), poor quality of life is associated with higher mortality in CVD 
patients. Thus, patient assessment protocols for CVD should combine clinical prognostic factors 
and self-reported quality of life scoring to identify those at risk of recurrent hospitalization and 
death. 
Despite a growing need to improve the quality in health care, a plurality of perspectives of the 
actual meaning of quality is available. Therefore, appropriate measures for quality improvement 
require the development of a shared understanding of this concept that enables clarity for 
practice (Beattie et al. 2012). HRQL is an appropriate self-reported measure of individuals’ 
emotional, social, and physical satisfaction (Thompson et al. 2002). It is used increasingly as a 
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measure of the outcome of CVD (Cepeda-Valery et al. 2011; O'Loughlin et al. 2010). HRQL has 
several components, including: life satisfaction, subjective welfare state, happiness, functional 
ability, and social welfare. Scales have been developed to quantify HRQL (Uneri and Cakın, 
2007). Quality of life can be a sign of quality of medical care and one part of the disease 
management programme. Therefore, instead of using classical measures like fatality to observe 
the results of medical care, quality of life can be used (Dehghanzadeh et al. 2001). 
HRQL is often measured in clinical studies, sometimes as the primary outcome (Roebuck et al. 
2001). Improvement in HRQL is increasingly cited as an outcome in clinical decision-making, 
assessment of treatment benefit (Treasure, 1999), care planning and nursing research (Uysal and 
Ozcan, 2011).  
The components of the HRQL have many things in common with the Institute of Medicine’s 
quality care dimensions. Therefore, the clarification of HRQL helps with the explication of 
quality of care, and ensures that the behaviour, attitudes and therapeutic relationships in care are 
retained by nurses (Beattie et al. 2012).  
HRQL scales may be either generic or disease-specific (Thompson and Roebuck, 2001). 
Disease-specific HRQL questionnaires relate to the course of a specified disease and its 
progression in specific patient populations, and yield high response rates, due to their relevance 
to respondents (Uysal and Ozcan, 2011). Disease-specific instruments are responsive to small 
changes in health status, and are less likely than generic instruments (Dempster and Donnelly, 
2000). Therefore, instruments developed to measure HRQL in specific clinical situations are 
proliferating (Roebuck et al. 2001). CVD is a key area for HRQL measurement, because most 
interventions aim to improve HRQL, as well as survival (Dougherty et al. 1998). Therefore, it is 
equally important that nurses be adequately prepared to assess HRQL in the growing population 
of patients with CVD (Mayberry et al. 2006). Treatments and interventions for CVD are 
evolving, increasing the demand for CVD-specific HRQL instruments (Roebuck et al. 2001).  
 
Background  
While many instruments for the measurement of health-related outcomes are available for 
instance, the Seattle, the Minnesota Living with Heart Failure questionnaire, the Kansas City 
Cardiomyopathy Questionnaire, and MacNew Questionnaire, most have not yet been adequately 
evaluated. Therefore, the evaluation of existing instruments in terms of validity and reliability 
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should have priority over the development of new instruments (Albers et al. 2010). It is believed 
that quality of life assessment can complement clinical prognostic markers to identify CVD 
patients at high risk of adverse health outcomes (Iqbal et al. 2010). 
The MI dimensional assessment scale (MIDAS) is a disease-specific questionnaire developed 
and tested for the evaluation of HRQL in UK patients (Thompson et al. 2002). Cultural 
adaptation, translation and psychometric properties of the original and translated versions of the 
UK MIDAS scale have been assessed in Mandarin (Wang et al. 2006), and Turkish (Uysal and 
Ozcan, 2011). These studies affirmed that the MIDAS scale is a valid and reliable questionnaire 
for the measurement of HRQL in patients with CVD living in different cultures and contexts.  
This instrument has been used and translated into different languages. It has been noted that 
several studies have been conducted using this scale since its initial introduction to the empirical 
published work. In addition, this scale has been found to possess high reliability and validity 
values in international research studies conducted in different countries (Yılmaz et al. 2011). It is 
known that if an instrument is to be used in a different languages and cultures, it is necessary to 
demonstrate that it has similar validity and reliability as the original instrument (Sencan, 2005; 
Urizar, 2006). However, to our knowledge, this questionnaire has not yet been translated into 
Persian. Therefore, this study was carried out to translate and assess the psychometric properties 
of the Persian version of MIDAS scale (MIDAS-P) using exploratory factor analysis.  
 
Study aim  
The study aimed to determine whether, and to what extent, MIDAS-P is a valid and reliable 
disease-specific HRQL scale in patients suffering from MI. 
Methods  
Study design  
This study was undertaken from June 2013 to March 2014 in Tehran, capital of Iran, where the 
lingua franca is Persian.  
Sample and Setting  
Patients’ notes were reviewed in relation to the inclusion criteria (below). All patients meeting 
the study’s inclusion criteria were approached one of the doctors on the research team. Nurses 
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informed participants of the study’s aims and obtained their informed consent. Three hundred 
and fifty participants were recruited from seven inpatient wards (after discharge from CCU) and 
outpatient departments at four university hospitals. The sample size was determined based on the 
rule that the number of the tool’s items is multiplied to 10. Thus, with MIDAS’s 35 items, 350 
patients were required (Knapp and Brown, 1995).  
Inclusion criteria were: 
 Persian speaker; 
  without previous psychiatric disorder; 
 without taking any  medicines for their mental health; 
 willing to participate in this research; 
 diagnosed with MI for the first time within the last three months; 
Exclusion criteria were: 
 lack of interest to participate in this study;  
 any change in the patients’ physical condition that might hinder participation 
 
Ethical considerations 
Written permission was obtained from Dr. David R. Thompson who held the copyright for the 
MIDAS. A licence for the SF-36 was obtained from Medical Outcome Trust. The study was 
approved and overseen by the research council affiliated to Shahed University [Registration 
code: 68412]. The ethics committee affiliated with Shahed University approved the study. 
Permission to approach patients was obtained from the teaching hospitals. Participants were 
provided with verbal information. Participants’ autonomy, confidentiality, and anonymity were 
respected throughout the study. Patients in this research were voluntary and participants were 
informed that they were free to withdraw from the study at any time without affecting their 
treatment.  
 
Data collection 
The study procedure and instruction for completing the questionnaires were expressed to 
participants who met the eligibility inclusion criteria by the first author. The HRQL instruments 
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were distributed and collected by the principal researcher one–two hours later. The 
questionnaire’s items were read to participants illiterate in Persian, and their answers recorded by 
a nurse.  
Instruments 
A three-part questionnaire was used:  
 Socio-demographic data were collected as outlined in Table 1. 
 MIDAS scale 
Quality of life was measured using the MIDAS scale (Thompson et al. 2002). This is a disease-
specific instrument for patients with MI. The MIDAS-P contains 35 items to quantify seven 
clinically relevant domains of CAD including ‘physical activity’, ‘insecurity’, ‘emotional 
reaction’, ‘dependency’, ‘diet’, ‘concerns over medication’ and ‘side effects’ (defined as the 
secondary effects of medicines, which may be positive or negative (ICH, 1996). Scores obtained 
in these domains are transformed and expressed from 0 to 100, where higher scores indicate 
worse HRQL.  
 SF-36 questionnaire 
HRQL was assessed against the SF-36 questionnaire, a general health related HRQL instrument, 
licensed from Medical Outcome Trust. The SF-36 consist: eight subscales including ‘physical 
functioning’, ‘bodily pain’, ‘general health’, ‘vitality’, ‘social functioning’, ‘role limitations due 
to physical problems’, ‘role limitations due to emotional problems’, and ‘mental health’. Scores 
in each scale range from 0 to 100, with zero representing the lowest HRQL and 100 showing the 
highest possible score. The original UK English and Persian versions of this questionnaire have 
high reliability and construct validity (Gandek and Ware, 1998; Montazeri et al.2005).      
Translation procedures and evaluation of content and face validity:  
After obtaining the authors’ written permission for the translation and application of the MIDAS, 
the questionnaire was translated as part of the international quality of life assessment project 
(IQoLAP) (Gandek and Ware, 1998). The IQOLA approach to translation and validation was 
developed for use with the SF-36, but is applicable to other healthcare measurement instruments. 
The MIDAS was translated from English to Persian by a nurse academic and a cardiologist 
independently. Differences were reconciled by discussion. The Persian version was back-
translated to English by a professional translator with no previous knowledge of the MIDAS 
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scale. The original scale and back-translated versions were compared item by item and a final 
Persian version of the scale was agreed by two bilingual experts. A multidisciplinary panel of 15 
health professionals and academics tested the content validity of the Persian questionnaire. The 
panel included: one expert in psychometrics, two cardiologists, six nurse instructors from three 
different universities in Tehran, and six experienced clinical nurses in Coronary Care Units 
(CCUs). They were asked to comment on the reasonability, suitability, attractiveness and logical 
sequence of the items as well as the conciseness and comprehensiveness of the questionnaire, 
and complete a Content Validity Index (CVI) (Gabe and Jordan, 2014). To assess face validity, 
the questionnaire was given to 10 patients who had suffered a MI within the three months to test 
comprehension and readability. Accordingly, some items were simplified and modified to 
improve the readability and understanding of the items by patients. Wording was changed in five 
items: 16- “ anxious about travelling?” was exchanged to “anxious about walking a long 
distance?’’; 20- “anxious about dying?” to “did you have fright of death and dying?;  29-“felt 
concerned about your diet?” to “did you take care of your diet condition?”; 30- “felt concerned 
about your cholesterol level?” to “did you notice your cholesterol level when selecting your 
diet?”; 34- “felt the cold more?” to “did you feel cold after taking your medicine?”.  
Two weeks after the initial survey of 350 patients was completed, the MIDAS-P was again 
passed to 70 patients who had previously responded and had agreed to complete the MIDAS-P 
twice.  
Data analysis 
SPSS software (version 16.0 for Windows; Chicago, IL, USA) was used for data analysis, 
following precedents set by the English language work (Thompson et al 2002). Patient 
characteristics and scores for each domain of the MIDAS-P were described. Construct validity of 
the MIDAS-P was investigated using exploratory factor analysis. Principal components analysis 
with varimax rotation was applied. The Kaiser-Meyer-Olkin test (KMO) and Bartlett’s Test of 
Sphericity were used to assess the appropriateness of the sample for the factor analysis. Eigen 
values above 1 and scree plot were used to select factors. Factor loadings equal or greater than 
0.4 were considered appropriate. For a known group comparison, the MIDAS-P scores of 
patients with and without smoking were checked for distribution and subjected to t-tests. To 
assess the concurrent validity of the MIDAS-P, Pearson’s correlation coefficients between the 
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subscale scores of the MIDAS-P and SF-36 were computed. Internal consistency of each scale of 
the MIDAS-P was determined using Cronbach’s alpha. 
Cronbach’s α coefficient of 0.7 or above was considered to be satisfactory (Schneider 2004). 
Test-retest reliability was calculated by computing the intraclass correlation coefficient (ICC) of 
each domain. An ICC >0.80 indicated good test–retest reliability and stability (De Boer, 2004).  
  
 Results 
 
Demographic Characteristics  
According to the international literature, socio-demographic factors can have significant impacts 
on the subjective well-being and quality of life of adults with CVD (Vigl et al. 2011) that should 
be considered for future comparisons between HRQL assessment instruments. In this study, of 
the 350 participants, 181 (51. 7%) were men. In addition, 248 (84.5%) were married. The mean 
age of participants was 69.40 [SD 6.01] years. Table 1 shows the demographic characteristics of 
the study sample.  
We assessed 350 patients’ records to assess eligibility. Only 2 patients did not meet the inclusion 
criteria due to lack of interest to participate in this study and being transferred to other wards, 
which were replaced by other patients. Therefore, 350 eligible patients were approached and 
recruited.  Most, (195) were recruited on hospital wards and 155 in outpatient departments. 
Participants took 10-15 minutes to complete the MIDAS-P questionnaire.  
Psychometric Properties of the Persian Version of the myocardial infarction dimensional 
assessment scale 
Content Validity Index (CVI) rated by the experts was value (0.95). Construct validity consisted: 
a) Exploratory factor analysis (EFA); The KMO coefficient was 0.86 exceeding the 
recommended value of 0.60 and Bartlett’s test of sphericity was significant x2 (595) = 
18860.10395 (p ≤ 0.001), showing sampling adequacy and confirming that the data were suitable 
and sufficient for factor analysis.  
A principal component analysis with varimax rotation was used to evaluate the construct validity 
of the questionnaire. After varimax rotation, 35 items loaded significantly on 6 factors. All 6 
factors had an eigenvalue greater than 1.0. Explained variance was 81.63%. The numbers of 
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items loading ranged from 6.74 to 26.03. No items were deleted (factor loading < 0.4). The Scree 
plot suggested generating a six-factor model (Fig. 1). 
By considering items with initial eigenvalues above 1 (Yu, 2009) and using a loading criterion of 
0.40 (Field, 2013), items of MIDAS-P were placed in six dimensions, unlike the English version 
of MIDAS, which had 35 items and 7 dimensions (Thompson et al. 2002). In the MIDAS-P, 
items 32-35 were loaded onto a factor labelled ‘Concerns over medication’. The factors of the 
MIDAS-P were:   
1. Physical activity (item numbers 1-12; 26.03% of observed variance);  
2. Insecurity (item numbers 13-21 ; 21.20% of observed variance);  
3. Emotional reaction (item numbers 22-25 ; 10.27% of observed variance);  
4. Dependency (item numbers 26-28 ; 9.75% of observed variance);  
5. Diet (item numbers 29-31 ; 7.62% of observed variance);  
6. Concerns over medication (item numbers 32-35; 6.74% of observed variance).  
The principal component analysis of the MIDAS-P is reported in Table 2. 
b) Discriminant validity; Non-smokers had significantly lower MIDAS-P scores than smokers in 
the domains of ‘insecurity’, ‘emotional reaction’, ‘dependency’, and ‘concerns over medication 
and side effects’ (Table 3). 
Convergent validity  
Findings showed correlation between MIDAS-P and SF-36 subscales. There were significant 
small-to-moderate levels of correlation between all the sub-scales: correlation coefficients ranged 
from 0.011 to 0.773 
The full MIDAS-P score demonstrated a significant and high correlation with the full SF-36 
score (r = 0.733, p < 0.01).  
Reliability of MIDAS-P was calculated with Cronbach's alpha internal consistency, item to total 
correlation and test–retest.  Cronbach's alpha for the total scale was measured 0.94, has 
acceptable internal consistency (Gliem & Gliem 2003). The six subscales’ alpha coefficients 
ranged from 0.82 to 0.96. Correlations between MIDAS-P subscales and total scores were 
positive, ranging 0.396 to 0.682, and significant. In test–retest reliability, the ICC coefficients 
ranged between 0.81 and 0.97, for the overall score, statistically significant (n=70, p < 0.001).  
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Discussion 
The aim of this study was to purpose the psychometric properties of the MIDAS-P.  Face and 
content validity were confirmed after minor revisions. Many studies in different cultures have 
assessed HRQL in patients with cardiac disease, particularly MI, and investigated the effects of 
nursing interventions on HRQL. However, such studies need standardised, valid and reliable 
questionnaires. 
Differences between the MIDAS-P and the English, Turkish and Mandarin versions of the 
MIDAS are summarized in Table 4.    
The main difference between the original and MIDAS-P was that the in this Persian version, sub-
scales of the ‘concerns over medication’ (consisting of two items, 32-33) and ‘side effects’ 
(consisting of two items 34-35) were integrated. Similarly, Uysal and Ozcan (2011) reported 
summarized subscales and deleted items 6, 9, 13, 15, 26, 28, 29, 30, 31, 34, and 35 in patients 
with MI. 
In order to adaptive CM-MIDAS to East-Asian culture and TR-MIDAS to Turkish and ensure 
that participants might more readily perceive it, item 16 was changed (Uysal and Ozcan, 2011; 
Wang et al. 2006). Similarly, in this research, item 34 was changed.  
In our research, CVI value (0.95) was higher than that (0.89) specified in Chinese version of 
MIDAS and similarly TR-MIDAS (0.95) (Uysal and Ozcan, 2011; Wang et al. 2006), indicating 
that the scale could be statistically evaluated without excluding any items. 
Exploratory factor analysis (EFA) was calculated to evaluate the construct validity, as for the 
CM-MIDAS and TR-MIDAS versions (Uysal and Ozcan, 2011; Wang et al. 2006), with a 
similar validity process (Waltz, 1993).  
In this study, the KMO value for sampling adequacy was high (0.86), and Bartlett's test of the 
model was statistically significant (p ≤ 0.001), as in the CM-MIDAS and TR-MIDAS versions 
(Uysal and Ozcan, 2011; Wang et al.  2006). The scree plot showed that the MIDAS-P had six 
factors: ‘physical activity’, ‘insecurity’, ‘emotional reaction’, ‘dependency’, ‘diet’, and ‘concerns 
over medication. This structure differs from the original (Thompson et al. 2002) and Mandarin 
versions (Wang et al. 2006). 
Total variance (81.63%) differed from that of CM-MIDAS (67.2%) and TR-MIDAS versions 
(65.15%) (Uysal and Ozcan, 2011; Wang et al. 2006). Following varimax rotation, subscales of 
medication side effects and concern over medication were removed and a new subscale with 4 
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items was added, which was different from the Chinese version of  MIDAS and TR-MIDAS  
versions (Uysal and Ozcan, 2011; Wang et al.  2006).    
Participants who smoked had significantly lower HRQL scores in five dimensions of the 
MIDAS-P including: ‘insecurity’, ‘emotional reaction’, ‘dependency’, and ‘concern over 
medication’, reinforcing messages on the negative impact of smoking.  
The MIDAS-P, the MIDAS and SF-36 HRQL questionnaires had significant small-to-moderate 
levels of correlation, as in previous studies (Yılmaz et al. 2011; Wang et al. 2006).  
The high level of internal consistency is partly attributable to the large number of items (Waltz, 
1993). Similar findings have been achieved in Cronbach's alpha values in the studies conducted 
using the English version of MIDAS, TR-MIDAS, and Chinese version of MIDAS with the 
patients population exposed to MI (Thompson et al. 2002; Uysal and Ozcan, 2011; Wang et al. 
2006).  
In this research, item to total correlation coefficients ranged 0.39-0.86, above the threshold for 
acceptability (>0.29) (Costa Santos et al. 2005; Yu, 2009). 
The MIDAS-P was assessed to the study participants twice—with a two-week interval. The 
lowest ICC coefficients were related to the ‘insecurity and dependency’ sub-scales, possibly 
representing a change in participants’ emotions. Others demonstrated less stability (Uysal and 
Ozcan, 2011; Wang et al. 2006).  
 
Conclusions 
The MIDAS-P has acceptable psychometric properties. This instrument introduces a 
modification of the quality of life after CVDو which was originally developed for those patients 
who survived a CVD event and referred for subsequent cardiac treatments. Since the healthcare 
indicators of Iran show a consistent improvement that are near those of developed countries, the 
results of this study can be generalized to other healthcare settings in both transitional and 
developed countries. It provides researchers, clinicians and especially clinical nurses with 
valuable additional information about the impact of either the condition or treatment from the 
patient's perspective, particularly in cardiac diseases as major causes of disability.  
The MIDAS-P is easy to understand and complete in ten to 15 minutes, and its acceptability is 
demonstrated by the response rates of over 90%. The MIDAS-P has potential for measuring 
health-related HRQL, determining the effects of medical and nursing interventions on patients’ 
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HRQL, increasing understanding of patients’ needs, and optimizing their treatments. The six 
factor solution with 35 items of MIDAS-P seems more appropriate than the seven factor version 
for patients exposed to MI in Iran. CVD impairs the function and mobility of the patient and also 
reduces his/her quality of life; The MIDAS scale-Persian version is demonstrated to have an 
acceptable reliability and validity in Iranian patients with CVD; it can be used to evaluate how 
daily activities, as well as physical, emotional, and social functioning are affected by the disease 
and its treatment process. This scale can be used to measure health outcomes in different clinical 
settings and research centres; moreover, it can be used by nurses for both measuring health-
related quality of life and determine the effects of different medical and nursing interventions on 
patients’ quality of life. Also, the Persian version of the MIDAS can be used by nurses and other 
clinicians to prepare future healthcare professionals who are capable to meet the needs of 
patients with CVD. 
Non-random sampling and a relatively small sample size restrict the generalizability of the study 
findings. This study involved patients in Tehran, and these findings should be tested in other 
regions of Iran. Consequently, multi-centre or multi-state studies with larger sample sizes are 
recommended. The high participation rate (100%), typical for research in our hospitals, indicates 
absence of volunteer bias, enhancing generalizability within the hospitals studied (Jordan et al. 
2013). We evaluated the validity and reliability of the MIDAS-P, but further work is needed to 
assess the responsiveness of MIDAS to changes in patients’ conditions. These findings would be 
strengthened by qualitative work to improve understanding of the patients’ perspectives of the 
factors delineated in the statistical analysis. In addition, longitudinal investigations evaluating the 
predictive nature of the identified MIDAS items are suggested.  
 
Key points for policy, practice and/or research 
o Health-related quality of life (HRQL) is an appropriate self-reported measure of 
individuals’ emotional, social, and physical satisfaction. 
o The MI dimensional assessment scale (MIDAS) is a disease-specific questionnaire 
developed and tested for the evaluation of HRQL in UK patients. 
o This study gave evidence of reliability and validity of the Persian Version of Myocardial 
Infarction Dimensional Assessment Scale. 
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o The MIDAS-P has potential for measuring health-related HRQL, determining the effects 
of medical and nursing interventions on patients’ HRQL, increasing understanding of 
patients’ needs, and optimizing their treatments. The six factor solution with 35 items of 
MIDAS-P seems more appropriate than the original seven factor version for patients 
exposed to MI. 
o This scale can be used easily by nurses for both measuring health-related quality of life 
and determine the effects of different medical and nursing interventions on patients’ 
quality of life. 
o Healthcare managers and nurse educators can use this instrument to make nurses familiar 
with the needs of patients with CVD and factors influencing patients’ quality of life and 
prepare them for the delivery of high quality care to the booming population of patients 
with CVD.  
o This comprehensible tool may enable the screening and detection of patients with CVD 
who may suffer from quality of life-related issues in the dimensions of physical activity, 
insecurity, emotional reaction, dependency, diet, and concerns over medication. 
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Table 1. Clinical and socio-demographic information of the patients (N = 350) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I: no limitation of 
ordinary activity 
II: slight limitation 
of ordinary activity. 
III: marked 
limitation of 
ordinary physical 
activity  
IV: unable to carry 
on any physical 
activity without 
discomfort 
 
 
 
 
 
 
Count (%)  
181(51.70) Male Gender 169(48.30) Female 
231(66.0) ≤70 
Age group (year) 99 (28.3) 71-80 
20(5.7) >80 
171(48.86) IlliterateEducation level 96(27.43) Primary school
66(18.86) High school 
17(4.85) Higher than diploma  
284(84.5) Married Marital status 66(15.5) Divorced & Widowed
164(46.86) EmployedEmployment status 35(10.10) Unemployed
108(30.86) Housewife
Economic status 43(12.28) Retried 199(56.9) Poor
151(43.1) Good
245(73.0) YesFamily history of CAD 102(37.0) No
22(6.28) I Functional class 70(20.02) II
99(28.28) III 
159(45.42) IV 
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Table 2. Principal component analysis of the IR-MIDAS (These items represent the back 
translation from Persian) 
Factor6 Factor5 Factor4 Factor3 Factor2 Factor1 Factors and Items 
      Physical activity 
     0.932 1-Thought twice before undertaking physical activity 
(such as housework or going to the shopping)? 
     0.956 2-Had angina symptoms (such as chest pain or 
tightness)? 
     0.836 3-Had angina (chest pain or tightness) that affected 
your life? 
     0.918 4-Felt slowed down? 
     0.703 5-Had no energy? 
     0.787 6-Been breathless? 
     0.928 7-Had chest pain or tightness when undertaking 
physical activity? 
     0.794 8-Felt frustrated at your limitations? 
     0.806 9-Needed to rest more? 
     0.858 10-Felt you have a reduced social life? 
     0.940 11-Felt you cannot perform your domestic duties? 
     0.714 12-Found the weather made your pain worse? 
      Insecurity 
    0.892 13-Worried or felt anxious about the future 
0.87514-Did you have fright of death and dying? 
 0.890 15-Felt frightened you will have another heart attack? 
 0.846 16-Felt isolated? 
 0.712 17-Felt lonely? 
 0.868 18-Felt anxious about walking a longer distance? 
 0.956 19-Felt vulnerable? 
 0.956 20-Felt insecure? 
    0.956  21-Been affected? 
      Emotional reaction 
 0.902  22-Felt irritable? 
 0.897  23-Felt down or depressed? 
 0.855   24- Felt bad tempered? 
 0.879  25-Felt stressed? 
Dependency
 0.943  26-Felt your family or friends are over protective? 
 0.871  27-Felt you have lost your independence? 
 0.903  28-Felt you have to rely on others? 
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Table 3. Known-group comparison between smokers and non-smokers of the IR-MIDAS 
Domain With experience of smoking   Without experience of smoking  p value Mean Score (SD) (n=171) Mean Score (SD) (n=179)
Physical activity  66.01(21.87) 44.26(23.09) .03 
Insecurity  61.53(26. 12) 29.99(11.79) .00 
Emotional reaction  56.95(25.74) 32.32(16.79) .00 
Dependency  59.49(26.95) 34.48(21.73) .01 
Diet situation  54.26(25.02) 39.10(23.62) .04 
Concerns over medication 61.98(26.23) 30.75(14.13) .00 
All variables were normally distributed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Differences between IR-MIDAS and other versions of the MIDAS 
Developmental stage IR-MIDAS 
(n=350) 
UK MIDAS 
(n=410) 
Turkish MIDAS 
(n=230 ) 
Mandarin MIDAS 
 (n=180 ) 
Factor analysis 6 factors 7 factors 6 factors 7 factors 
KMO 0.86 0.87 0.82 0.87 
  Diet situation  
0.904 29-Worried about your weight?
0.927  30- Did you take care of your diet? 
0.730  31-Did you notice the importance of diet for your 
cholesterol level? 
      Concerns over medication
0.884      32-Worried about taking medicines? 
0.842      33-Worried about side effects from your medicines? 
0.838      34- Did you feel that you were colder after you took your medicine Felt the cold more? 
0.899      35-Experienced unwanted side effects 
   *Kaiser-Meyer-Olkin measure of sampling adequacy=0.80, Bartlett's test of Sphericity 
was significant (p < 0.001). 
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The Bartlett's 
test 
x2(595) = 
18860.10395 
- x2(276)= 
2612.375 
x2 (595) = 
4065.145 
Total variance 
(%) 
81.63 70.8 65.15 67.18 
Item to total 
correlation 
0.39 -0. 86 - 0.34 to 0.84 0.68 - 0.89 
total variance 81.63%  65.15% 67.2% 
Coronbach’s 
alpha 
 
0.82 - 0.96 0.71–0.94 0.65 to 0.88 0.71–0.93 
Known group 
comparison 
smoking and 
without smoking 
- - - 
reliability  
Test-retest 
ICC 
0.814- 0.970 0.34 - 0.84 0.41–0.86 0.74–0.94 
Correlation with 
SF36 
0.011 to 0.77 0.121- 0.76 - 0.042 to-0.78 
 
 
 
 
Figure 1: Scree plot of generating a six-factor model 
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